Your session is about to expire
← Back to Search
Amoxicillin for Pneumonia (STAMPP Trial)
STAMPP Trial Summary
This trial will test if treating mild CAP in young children without antibiotics is as effective as with antibiotics, with fewer side effects.
- Pneumonia
- Respiratory Diseases
- Antibiotic Use
- Community-acquired Pneumonia
STAMPP Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.STAMPP Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this research offering open to people aged 35 and above?
"In accordance with this medical trial's inclusion criteria, the lower limit of age is one year old and the upper boundary is slightly below six years."
Is the enrollment phase of this trial still open?
"According to the details published on clinicaltrials.gov, this experimental endeavour is currently seeking participants and was initially listed online on 9 January 2023 with its most recent edit being made 3 February of that year."
Has the Federal Drug Administration sanctioned Amoxicillin for use?
"We rate the safety of Amoxicillin as a 3 due to it being in Phase 4; indicating that this medication already has been approved."
How many participants are engaged in this clinical research?
"Affirmative, the information on clinicaltrials.gov indicates that this study is actively soliciting volunteers. The medical trial was initially published on September 1st 2023 and edited most recently on February 3rd of the same year. Ten individuals are meant to be recruited from a single site."
Would I be eligible to participate in this medical trial?
"For this medical investigation, 10 individuals with pneumonia aged between 1 and 59 months must meet the following prerequisites: mild symptoms (as determined by a healthcare provider); fever; confirmed diagnosis of community-acquired pneumonia; intention to be treated as an outpatient post ED/primary care visit."
Share this study with friends
Copy Link
Messenger